Preformulation and pharmacokinetic studies on antalarmin: A novel stress inhibitor

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 205-214

  Sanghvi, Ritesh ^a   Mogalian, Erik ^a   Machatha, Stephen G ^b   Narazaki, Ryuichi ^c   Karlage, Kelly L ^a   Jain, Parijat ^a   Tabibi, S Esmail ^d   Glaze, Elizabeth ^d   Myrdal, Paul B ^a   Yalkowsky, Samuel H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b CyDex LC   (United States)

^c EISAI CO LTD   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antalarmin; Complexing agents; Cosolvent; Lipid based formulation; Solubility; Surfactant

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALCOHOL; ALPHA TOCOPHEROL; ANTALARMIN; BETA CYCLODEXTRIN; CETRIMIDE; CLOGP; CREMOPHOR; DODECYL SULFATE SODIUM; GELUCIRE; LABRASOL; MACROGOL 400; NICOTINAMIDE; OLEIC ACID; POLYSORBATE 80; PROPYLENE GLYCOL; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; INTESTINE FLUID; PH; PREFORMULATION; SUSPENSION;

EID: 58149267689     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21421     Document Type: Article

References (27)

1. Perrut M, Jung J, Leboeuf F. 2005. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: Micronization of neat particles. Int J Pharm 288:3-10.
2. Biradar SV, Patil AR, Sudarsan GV, Pokharkar VB. 2006. A comparative study of approaches used to improve solubility of roxithromycin. Powder Tech 169:22-32.
3. Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, Varia SA, Serajuddin ATM. 2004. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm 269:251-258.
4. Ran Y, Jain A, Yalkowsky SH. 2005. Solubilization and preformulation studies on PG-300995 (An Anti-HIV drug). J Pharm Sci 94:297-303.
5. Jain N, Yang G, Tabibi E, Yalkowsky SH, 2001. Solubilization of NSC-639829. Int J Pharm 225: 41-47.
6. Porter CJ, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 3:231-248.
7. Hauss D. 2007. Oral lipid-based formulation. Adv Drug Deliv Rev 59:667-676.
8. Pouton CW. 2006. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid-formulation classification system. Eur J Pharm Sci 29:278-287.
9. Constantinides PP, Wasan KM. 2004. Advances in lipid-based drug solubilization and targeting. Adv Drug Deliv Rev 56:1239-1240.
10. Sha X, Yan G, Wu Y, Li J, Pang X. 2005. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 24:477-486.
11. Rama Prasad YV, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N, Takada K. 2003. Enhanced intestinal absorption of vancomycin with Labrasol and D-α-tocopheryl PEG 1000 succinate in rats. Int J Pharm 250:181-190.
12. O'Driscoll CM. 2002. Lipid-based formulation for intestinal lymphatic delivery. Eur J Pharm Sci 15:405-415.
13. Charman WN, Stella VJ. 1986. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 34: 175-178.
14. Porter CJH, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Oral Drug Absorption: A Renaissance. Bull Tech Gattefosse 94:119-139.
15. Yang S, Gursoy RN, Lambert G, Benita S. 2004. Enhanced oral absorption of Paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21:261-270.
16. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. 2004. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278:119-131.
17. Webster EL, Lewis DB, Torpy DJ, Zachman K, Rice KC, Chrousos GP. 1996. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotrophin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137: 5747-5750.
18. Wade A, Weller PJ. 1994. Handbook of Pharmaceutical Excipients. 2nd edition. American Pharmaceutical Association. Washington DC.
19. Zhang C, Suslick KS. 2007. Colorimetric sensor array for soft drink analysis. J Agric Food Chem 55:237-242.
20. Yalkowsky SH, Roseman TJ. 1981. Techniques of solubilization of drugs. Chapter 3. New York: Dekker.
21. Millard JW, Alvarez-Núñez FA, Yalkowsky SH. 2002. Solubilization by cosolvents: Establishing useful constants for the log-linear model. Int J Pharm 245:153-166.
22. He Y, Tabibi SE, Yalkowsky SH. 2005. Solubilization of two structurally related anticancer drugs: XK-469 and PPA. J Pharm Sci 95:97-107.
23. 7M-β-CD to HP-β-CD. Pharm Res 18:667-673.
24. Sanghvi R, Evans D, Yalkowsky SH. 2007. Stacking complexation by nicotinamide: A useful way of enhancing drug solubility. Int J Pharm 336: 35-41.
25. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45:89-121.
26. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW. 2000. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci 97:6079-6084.
27. 1 receptor antagonist. J Med Chem 40:1749-1754.